Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Weekly Turoctocog Alfa Pegol Feasible for Hemophilia A

Key clinical point: Some patients with severe hemophilia A can be managed with weekly injections of the recombinant factor VIII (rFVIII) product turoctocog alfa pegol (N8-GP).

Major finding: The median annualized bleeding rate was 0.00 days, regardless of whether patients received N8-GP every 4 days or every 7 days.

Study details: An extension of the phase 3 pathfinder 2 trial that involved 55 patients with two or fewer bleeding episodes during the preceding 6 months of the main trial.

Disclosures: The study was funded by Novo Nordisk. The investigators reported financial relationships with Bayer, CSL, Novo Nordisk, Octapharma, Genentech, Shire, and others.

Citation:

Curry N et al. Haemophilia. 2019 Feb 28. doi: 10.1111/hae.13712.